The specter of generic challenges has consistently loomed over copyright’s famous drug, Sildenafil, sparking questions about the prospects of connected medicinal stakes. While initial times saw substantial profits, the exclusivity lapse has opened the door knockoff for discounted alternatives, potentially lowering earnings and creating a real dan